The Russian Direct Investment Fund announced the registration of the Russian single-component anti-COVID19 Sputnik Light vaccine by the Ministry of Health of the Bolivarian Republic of Venezuela and the registration of the Russian Sputnik V vaccine in the Republic of Ecuador.
The Sputnik Light vaccine is the first component (recombinant human adenovirus 26 serotype (rAd26)) of the Sputnik V vaccine. The efficacy of the single-component Satellite Light vaccine is 79.4% from the 28th day after immunization.
In January of this year, a two-component Sputnik V vaccine was also registered in Venezuela. The drug was approved for use as part of an accelerated procedure (emergency use authorization, EUA).
Thus, Sputnik V is registered in 66 countries with a total population of over 3.2 billion people. Registration in Ecuador was carried out as part of the accelerated procedure (emergency use authorization, EUA).
